Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer-Reference-Cited by-同舟云学术

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer

Published:2023-02-28 Issue:3 Volume:43 Page:1273-1282
ISSN:0250-7005
Container-title:Anticancer Research
language:en
Short-container-title:Anticancer Res

Author:

WAGNER SANDRO M.,MAGNES TERESA,MELCHARDT THOMAS,KIEM DOMINIK,WEISS LUKAS,NEUREITER DANIEL,WAGNER CHRISTINA,ARETIN MARIE-BERNADETTE,NEMEC STEFAN,GAMERITH GABRIELE,PALL GEORG,GREIL RICHARD,FUEREDER THORSTEN

Publisher

Anticancer Research USA Inc.

Subject

Cancer Research,Oncology,General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancement of Tumor Antigen-specific T-cell Responses by Immune Checkpoint Blockade in Human Papillomavirus-related Head and Neck Squamous Cell Carcinoma;Anticancer Research;2024-06-26

2. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG);European Archives of Oto-Rhino-Laryngology;2024-05-25

3. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis;BMC Cancer;2024-04-08

4. Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis;Anticancer Research;2024-02-29

5. Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab;International Immunopharmacology;2023-10